ProKidney Corp. reported mixed top-line results in its Phase II REGEN-007 trial evaluating rilparencel, an autologous cell therapy for chronic kidney disease (CKD) in diabetic patients. One cohort receiving two doses saw a significant 78% improvement in annual kidney function decline, while a second cohort showed a non-significant 50% improvement with a single dose. No safety concerns were linked to treatment. The company aims to leverage these data for accelerated FDA approval and has initiated a Phase III PROACT 1 trial.